Among human immunodeficiency type 1 viruses (HIV-1) isolated during long-term 3'-azido-3'-deoxythymidine (AZT) therapy, 4 condons (Asp67, Lys70, Thr215, and Lys219) in the HIV-1 reverse transcriptase (RT)-coding region have been considered to be related to the AZT resistance of HIV-1. Therefore we determined these mutation patterns in HIV-1 isolates from patients undergoing long-term AZT treatment. In 41 clones of HIV-1 from 7 patients, the Thr215 mutation was the most predominant (97.6%), and more frequent than Asp67 (48.8%), Lys70 (31.7%) and Lys219 (9.8%) mutations.
Introduction
For prevention and therapy of acquired immunodeficiency syndrome (AIDS), the hypervariability of human immunodeficiency type 1 virus (HIV-1) has raised many obstacles. Hypervariability in the envelope coding region has hindered the development of an HIV vaccine and immunoprophylactic measures. Hypervariability in the reverse transcriptase (RT)-coding region has raised concerns regarding long-term anti-retroviral therapy with 3'-azido-3'-deoxythmidine (AZT). Because the RT-coding region of HIV-1 is the target of nucleoside analogues such as AZT, multiple mutations in HIV-1 RT are thought to be correlated with a high level of resistance to AZT. Comparative nucleotide sequence analysis of the RT-coding region from AZT-sensitive and AZT-resistant HIV-1 To determine the mechanism of AZT resistance after long-term AZT treatment in hopes of improving anti-retroviral therapy, we isolated HIV strains from patients treated with AZT at various times during therapy and compared the mutation patterns in amino acid residues in the RT region of those strains with the patterns of the AZT-susceptible wild type HIV-1 strains. In this paper we report 1) the prevalence of mutation at each of the 4 codons in isolates obtained after long-term AZT therapy, 2) amino acid mutation patterns of these HIV-1 isolates grown in the presence or absence of AZT, 3) comparison of HIV-1 mutations over time, and 4) changes in nucleotide mutation patterns in individuals over the course of AZT treatment and the susceptibility of each isolate to AZT. Results 1) Prevalence of amino acid mutants in the RT-coding region of HIV-1 isolates from patients treated with AZT for longer than 6 months. HIV-1 isolates were obtained from 9 patients treated with AZT for longer than 6 months. From these, 48 HIV-1 RT-coding clones were obtained and sequenced. Fourty-one of the 48 clones showed mutation in the RT-coding region at 1 or more of codons 67, 70, 215, or 219. These mutants were isolated from 7 of 9 patients (77.8%).
Among the 41 mutant clones, mutations at codons 67, 70, 215, and 219 were observed in 48.8, 31.7, 97.6 and 9.8 % respectively (Table 1) . It is worthynoting that almost all mutants showed a mutation at codon 215. 2) Amino acid mutation patterns of 22 HIV-1 RT-coding clones from isolates grown in the presence Table 1 Prevalence of amino acid mutations in the RT-coding region of HIV-1 isolates from patients with long-term AZT treatment Table 3 HIV mutations at 4 codons over time in patients treated with AZT 
Discussion
We found 41 HIV-1 RT-coding clone mutants among 48 clones obtained from 10 isolates from 9 patients who underwent long-term AZT therapy. As it has been reported that Asn67, Lys70, Thr215, and Lys219 RT mutations are associated with AZT resistance1-3), we determinedthe occurrence of these 4 codon mutations among our HIV-1 mutants. Of these 4 mutant amino acid, Thr215 was observed quite frequently (40 of 41 or 97.6%) compared with other codon mutations. Asp67 occurred in only 48.8% of the clones, Lys70 in 31.7%, and Lys219 in 9.8%. These results showed the possibility of predominance of codon 215 mutation in AZT resistance after long-term AZT therapy.
We tried to culture HIV-1 from patients treated with AZT for 6 to 31 months in the presence of 1 ,uM AZT. Assuming that the concentration of AZT in the blood 4 hours after a 250 mg dose (given every 4 hours) is 0.94-1 ,umol/L10), 1 ,uM in vitro represents an appropriateconcentration to determine AZT resistance in vivo. Twenty-two HIV-1 clones were obtained from these long-term AZT-treated patients by culture with AZT; their amino acid mutation patterns in the RT-coding region were compared with those of clones obtained from the same patients by culture without AZT. Among 22 clones with AZT and 17 clones without AZT, the codon 215 (Thr) mutation was observed in all isolates. By contrast, of the clones cultured with AZT, Asn67, Lys70, and Lys219 mutation was observed in only 18.2, 36.4 and 31.8% respectively. These 3 amino acid mutation patterns were more frequently found in isolates grown in the absence of AZT (52.9-58.8%) than inthose grown in its presence (18.2-36.4%).
These results also demonstrate that the codon Thr215 mutation in the RT-coding region plays a more important role in AZT resistance than the other3 amino acid mutations. Asp67 mutation to Asn, which was observed in isolates cultured without AZT, was not observed in isolates cultured with AZT. These findings suggest a rather minorrole for Asp67 mutation in AZT resistance.
In 14 of 22 (63.6%) mutant clones grown in the presence of AZT, and in 7 of 17 (41.2%) grown without AZT, the single amino acid substitution (Thr215 to Tyr) was the only mutation found. This finding underlines the predominance of this particular mutation of HIV-1 in relation to AZT resistance in long-term AZT treatment. In contrast to this single amino acid mutation among AZT-resistant isolates, the other Thr215 mutants (Thr215 to Phe) are all associated with 2 or 3 additional amino acid mutations in Asp67, Lys70 or Lys219.
The appearance of HIV-1 mutations in these 4 codons was investigated over thecourse of AZT treatment. Growth of HIV-1 isolates cultured in the presence of AZT was not observed before of AZT therapy, but the virus appeared after 6-7 months. The low rate of Thr215 mutation in the early stage of AZT treatment and extremely high rate of Thr215 mutation in later stages, such as after 6 months of AZT therapy, demonstrates the predominant role of Thr215 mutation in AZT resistance. This is in contrast to Lys70 mutation which was frequently observed in the early stage but decreased in later stages.
The nucleotide sequences of 2 patients individually followed up clinically are shown in Table 4 . After 2 months of AZT treatment, the observed mutations had only 1 nucleotideshift, codon 70 from AAA to AGA or codon 215 from ACC to CCC, and these isolates were not resistant to AZT. However, the codon 215 mutation from ACC to TAC (Tyr) or TTC (Phe) observed in AZT-resistant isolates after 8 or 12 months of therapy are 2-nucleotide mutations. This may explain the late appearance of the predominant mutation pattern of Thr215 to Phe or especially to Tyr in relation to AZT resistance. Single nucleotide mutations such as codon 70 from AAA to AGA which appear in the early stages of AZT therapy may not play such a significant role in acquisition of AZT resistance by HIV-1.
